Abstract

Despite close to two decades of antiretroviral therapy (ART) in Nigeria, data on late on-onset ART-associated adverse drug reactions (ADRs) are sparse. To describe early and late-onset ADRs and compare their incidence in an outpatient HIV positive Cohort on ART. We described the incidence of clinical ADRs identified and documented in an outpatient clinic cohort of HIV-positive patients treated between June 2004 and December 2015 at a tertiary health facility in Nigeria. Incidence rates of ADRs during the first and subsequent years of ART were compared. of the 13,983 patients' data analyzed, 9317 were females (66%), and those in the age bracket of 25 to 45 years made up 78% of the studied population. During 52,411 person-years (py) of ART, 1485 incident ADRs were recorded; Incidence rate (IR) 28.3 (95% confidence interval [CI] 26.9:29.8) ADRs per 1000 person-years (py) of ART. The IR of ADRs was about two times higher in the first year of ART compared to subsequent years of treatment; crude incidence rate ratio (IRR) 1.77 (95% CI 1.59:1.97). Anemia, hypersensitivity reactions, and nervous system disorders had 7, 23, and 5 times higher incidence, respectively, in the first year of therapy, compared to subsequent years. The first year of ART is the period of highest risk of ADRs. Individual and programmatic treatment success in resource-limited settings requires strategies for early identification and management of ADR during the period of greatest risk of ADRs.

Highlights

  • Available data indicate that there is an upsurge in the number of human immune deficiency virus (HIV) infected persons accessing life-saving antiretroviral therapy (ART) globally

  • We described the incidence of clinical adverse drug reactions (ADRs) identified and documented in an outpatient clinic cohort of HIV-positive patients treated between June 2004 and December 2015 at a tertiary health facility in Nigeria

  • The Incidence rate (IR) of ADRs was about two times higher in the first year of ART compared to subsequent years of treatment; crude incidence rate ratio (IRR) 1.77

Read more

Summary

Introduction

Available data indicate that there is an upsurge in the number of human immune deficiency virus (HIV) infected persons accessing life-saving antiretroviral therapy (ART) globally. As of December 2018, of the 37.9 million people living with HIV worldwide, 23.3 million (61%) were on treatment, more than three times as African Health Sciences. Antiretroviral therapy-associated ADRs are risk factors for poor health outcomes and mortality in people living with HIV . This study described early and late-onset ADRs in an outpatient clinic cohort of people living with HIV on ART. Despite close to two decades of antiretroviral therapy (ART) in Nigeria, data on late on-onset ART-associated adverse drug reactions (ADRs) are sparse.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call